MP04-Inmunogenética Enfermedades Sistémicas y Cutáneas
Medicina de Precisión / IBS-MP04
El grupo de investigación se centra en el estudio de los marcadores inmunogeneticos y su relación con los mecanismos inmunopatológicos de enfermedades autoinmunes con especial interes en la enfermedad inflamatoria intestinal. En una segunda línea de trabajo relacionada con la Oncología Cutánea analiza el efecto de elementos genéticos en la predisposición, desarrollo y evolución del melanoma.
Palabras clave
Autoinmunidad Inmunogenetica Enfermedad Inflamatoria Intestinal (IBD) Psoriasis Alopecia Areata Melanoma Carcinoma Baso Celular y Carcinoma Epidermoide Citocinas, quimiocinas HLA TLR, NOD-2, Inflamasoma.
MARIA JOSE CABELLO TAPIA
MIGUEL ANGEL LOPEZ NEVOT
Inventores: MIGUEL ANGEL LOPEZ NEVOT,JOSEFA LEON LOPEZ,ANA GILA MEDINA,JOSÉ ANTONIO MUÑOZ GÁMEZ,ROSA QUILES PÉREZ,PALOMA MUÑOZ DE RUEDA,ÁNGEL CARAZO GALLEGO,ESTHER JOSÉ PAVÓN CASTILLERO,ANA BELÉN MARTÍN ÁLVAREZ,FCO JAVIER SALMERON ESCOBAR
Título: POLIMORFISMOS PARA PREDECIR O PRONOSTICAR LA RESPUESTA AL TRATAMIENTO ANTIVIRAL
Código: P201430205
Inventores: JAVIER SALMERÓN ESCOBAR;PALOMA MUÑOZ DE RUEDA;ROSA QUILES PÉREZ;JOSE ANTONIO MUÑOZ GAMEZ;ESTHER JOSÉ PAVÓN CASTILLERO;ANA GILA MEDINA;MIGUEL ANGEL LOPEZ NEVOT;JORGE CASADO RUIZ;ANGELES RUIZ EXTREMERA;ANA BELÉN MARTÍN;ANGEL CARAZO GALLEGO;JOSEFA LEÓN
Título: Mutaciones específicas (L5P; L7P; L15S) en el epítopo inmunodominante VHC-NS3 (aa 1253-1272) frente al HLA-DQB1*0301 provocan una no respuesta al tratamiento antiviral con pegIFN/RBV en pacientes con Hepatitis Crónica C genotipo
Código: P-06781
Inventores: JOSE ANTONIO LOPEZ ESCAMEZ, MIGUEL ANGEL LOPEZ NEVOT, IRENE GAZQUEZ PÉREZ
Título: MÉTODO DE OBTENCIÓN DE DATOS ÚTILES PARA EL DIAGNOSTICO Y PRONÓSTICO DE LA HIPOACUSIA NEUROSENSORIAL
Código: P201132013
Clinical Case: Patient with Mixed Graft Rejection Four Days after Kidney Transplantation Developed Specific Antibodies against Donor Bw4 Specificities.
ANTIBODIES, 2021;
Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium
JOURNAL OF FUNGI, 2021;
FI:5,816; Q1
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
FRONTIERS IN IMMUNOLOGY, 2021;
FI:7,561; Q1
Measurement of 45 cytokine, chemokine and growth factors in established cell culture supernatants and autologous serum from advanced melanoma patients
CARCINOGENESIS, 2021;
FI:4,944; Q2
Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis
JOURNAL OF ONCOLOGY, 2021;
FI:4,375; Q2
Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium
BLOOD CANCER JOURNAL, 2020;
FI:8,023; D1
NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium
SCIENTIFIC REPORTS, 2020;
FI:3,998; Q1
Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis
INFECTION AND IMMUNITY, 2020;
FI:3,201; Q2
Joint study of the associations of HLA-B and the transmembrane short tandem repeat polymorphism of MICA protein with alopecia areata shows independent associations of both with the disease
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020;
FI:1,977; Q3
Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium
SCIENTIFIC REPORTS, 2019;
FI:4,011; Q1
Asymptomatic Leishmania infection in blood donors from the Southern of Spain
INFECTION, 2019;
FI:2,927; Q2
Study of Human Leukocyte Antigen (HLA) in 13 cases of familial frontal fibrosing alopecia: CYP21A2 gene p.V281L mutation from congenital adrenal hyperplasia linked to HLA class I haplotype HLA-A*33:01; B*14:02; C*08:02 as a genetic marker
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019;
FI:1,701; Q3
Familial frontal fibrosing alopecia: A cross-sectional study of 20 cases from nine families
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019;
FI:1,701; Q3
Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018;
FI:7,357; D1
Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018;
FI:4,287; Q1
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017;
FI:9,566; D1
CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS)
CLINICAL GENETICS, 2017;
FI:3,326; Q2
Apremilast, beyond psoriasis as a therapeutic target
MEDICINA CLINICA, 2017;
FI:1,125; Q3
Is it safe to use N-acetylcysteinein the treatment of bilateralectropion on collodion baby?
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017;
FI:1,56; Q3
Successful treatment of proliferative verrucous leukoplakia with 5% topical imiquimod
DERMATOLOGIC THERAPY, 2017;
FI:1,093; Q4
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn’s Disease
JOURNAL OF CROHNS & COLITIS, 2016;
FI:6,585; D1
Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients
FRONTIERS IN PHARMACOLOGY, 2016;
FI:4,418; Q1
Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium
INFECTION AND IMMUNITY, 2016;
FI:3,603; Q1
Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands
SCIENTIFIC REPORTS, 2016;
FI:5,228; Q1
MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016;
FI:3,148; Q2
Mechanisms of solvent resistance mediated by interplay of cellular factors in Pseudomonas putida
FEMS MICROBIOLOGY REVIEWS, 2015;
FI:13,244; D1
Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: a two-stage case-control study
PHARMACOGENETICS AND GENOMICS, 2015;
FI:3,481; Q1
Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study
PHARMACOGENETICS AND GENOMICS, 2015;
FI:3,481; Q1
Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal
INFLAMMATORY BOWEL DISEASES, 2015;
FI:4,464; Q1
Association of haplotypes of the TLR8 locus with susceptibility to Crohn’s and Behcet’s diseases
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015;
FI:2,724; Q2
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE (To-ReWard Study)
Financiador: PÉREZ GISBERT, JAVIER
Tipo de prueba: ESTUDIO POSAUTORIZACION INDEPENDIENTE
Tiempo de ejecución: 24/06/2021 - 30/03/2022
IP: MARIA JOSE CABELLO TAPIA
A phase 2b, double-blind, randomized, placebo-controlled, parallel group, dose ranging study of oral PF-06651600 and PF-06700841 as induction and chronic therapy in subjects with moderate to severe uncerative colitis
Financiador: PFIZER INC
Tipo de prueba: ENSAYO CLINICO COMERCIAL
Tiempo de ejecución: 26/09/2017 - 30/09/2020
IP: MARIA JOSE CABELLO TAPIA
Estudio en fase IIA aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para evaluar la eficacia y la seguridad de PF-06651600 y PF06700841 por via oral como tratamiento de induccion y de extension abierta en pacientes con Enfermedad de Crohn moderada o grave
Financiador: PFIZER INC
Tipo de prueba: ENSAYO CLINICO COMERCIAL
Tiempo de ejecución: 27/06/2018 - 28/02/2021
IP: MARIA JOSE CABELLO TAPIA
Estudio de busqueda de dosis de fase II,multicentrico, aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de IMU-838 en terapia de induccion y mantenimiento en colitis ulcerosa de moderada a grave. CALDOSE I
Financiador: IMMUNIC AG
Tipo de prueba: ENSAYO CLINICO COMERCIAL
Tiempo de ejecución: 30/05/2018 - 22/01/2020
IP: MARIA JOSE CABELLO TAPIA